Contact Us
Drug Search Results
More Filters [+]

Nedaplatin

Alternative Names: nedaplatin
Latest Update: 2024-07-29
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Cisplatin Analogue

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nedaplatin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Squamous Cell Carcinoma

Phase 3: Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer

Phase 2: Squamous Cell Carcinoma|Esophageal Cancer|Nasopharyngeal Cancer|Head and Neck Cancer|Uterine Cancer|Cervical Cancer

Phase 1: Esophageal Cancer|Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NPC-NDP

P3

Recruiting

Nasopharyngeal Cancer

2028-06-30

SHR-1316-HLJ-005

P2

Not yet recruiting

Squamous Cell Carcinoma|Esophageal Cancer

2027-05-30

ChiCTR2400083452

N/A

Recruiting

Esophageal Cancer

2027-04-30

NCT05039606

P2

Not yet recruiting

Head and Neck Cancer|Squamous Cell Carcinoma

2026-09-01

Recent News Events

Date

Type

Title

04/22/2024

PubMed

 The Ability of Clinically Relevant Chemotherapeutics to Induce Immunogenic Cell Death in Squamous Cell Carcinoma.

04/06/2024

PubMed

 Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial.

03/26/2024

PubMed

 Multiple molecular and cellular mechanisms of the antitumour effect of dihydromyricetin (Review).

12/31/2021

News Article

 Research Report on China's Lobaplatin Market, 2021-2025 Featuring Hainan Changan International Pharmaceutical

09/03/2020

News Article

 Small Molecule Cancer Drugs Industry Report 2020-2026 - Clinical Trials Insight on >2,500 Drugs by Phase, Company, Country, Formulation and Indication

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions